Wealth and Knowledge Report

Propanc Biopharma’s Lead Product Receives Orphan Drug Designation from the FDA 

2017 has presented itself as a critical time for investors as PPCB’s lead product, PRP, takes the biotech world by storm.

World Changing Opportunity for Cancer Patients
Cancer knows no boundaries. Either you or someone you know has been either directly or indirectly affected by this terrible disease.  To bring some perspective to how devastating cancer is, the World Health Organization published these absolutely astounding statistics predicting an increase of deaths related to cancer.

It is expected that the world will see…
10 Million Deaths from cancer by 2020
13 Million Deaths from cancer by 2030

Fortunately, companies like Propanc Biopharma, Inc. (PPCB) are working on treatments that could drastically lower these shockingly high death toll predictions. PPCB is well on its way well to changing the outcome for patients suffering from some of the deadliest cancers, including pancreatic cancer. Pancreatic cancer is one of the deadliest, if not the deadliest, cancer. This diagnosis gives patients a median survival rate of 6 months and less than 5% of patients live up to 5 more years.

Propanc Biopharma, Inc. (PPCB)

Watch this video on what we think may be one of the most exciting investment opportunities on the market today.

Propanc Biopharma (PPCB)’s PRP Treatment

PPCB’s lead product, PRP, is a novel, patented, formulation consisting of two proenzymes mixed in a synergetic ratio that targets solid tumors. PRP is a long-term therapy base on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis, the main cause of patient death from cancer. The Company’s initial target patient populations include pancreatic, ovarian and colorectal cancers.

 

How PRP Works

PRP’s anti-cancer effects block tumor growth and aggressive dissemination by:

  • Controlling cancer cell migration
  • Increasing the expression of the protein responsible for cell-to-cell contact
  • Inhibiting tumor blood vessel formation
  • Strongly suppressing cell invasion and metastasis
  • Triggering cell death
  • Enhancing the body’s own immune system

 

FDA GRANTS ORPHAN DRUG DESIGNATION FOR PPCB’s LEAD PRODUCT, PRP

On June 26th, 2017, Propanc Biopharma Inc. (PPCB) announced that the FDA approved their Orphan Drug Designation (ODD) for the use of PRP. Under the Orphan Drug Act (ODA), drugs, vaccines, and diagnostic agents qualify for orphan status if they are intended to treat a disease affecting less than 200,000 American citizens. Under the ODA, orphan drug sponsors qualify for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), tax credits of up to 50% of R&D costs, R&D grants, waived FDA fees, protocol assistance, and may get clinical trial tax incentives. This designation helps crucial drug treatments, such as PRP, move to the medical market faster, increasing the chance to save lives.

PRP is making headway through the cancer research world as a solution for once daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen, for the treatment of pancreatic cancer. As PRP moves toward First-In-Man Studies, the goal is for the solution to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. The World Health Organization stated that 8.2 million people died from cancer in 2012. A recent report published by IMS Health, stated that innovative therapies are driving the global oncology market to meet demand. The market expected to reach $150 Billion by 2020. 

“I am extremely proud of my team for this achievement, which has been a number of years in the making,” said James Nathanielsz, Propanc Biopharma’s Chief Executive Officer. “We are now firmly focused on the hard work ahead of us to proceed into First-In-Human studies as soon as possible. Receiving ODD from the FDA provides us with tremendous confidence we are on the right path, and the potential benefits to fast track the development process and receive attractive benefits for up to seven years when we achieve market approval, is very exciting for an emerging biopharmaceutical company like ours. I am truly grateful to our shareholders who continue to support our company. I hope this encourages investors to see the true value of our technology.”

 

 

PPCB Milestones Achieved in Q1 2017

    • Approved patent allowance in the US for lead product PRP which aims to prevent tumor recurrence and metastasis in solid tumors.
    • Successful completion of low dose group for GLP-compliant 28-Day repeat-dose toxicity study.
    • Currently in formal preclinical development and progressing toward First-In-Man studies.
    • Effectuated reverse stock split to uplist company and completed a 1-for-250 reverse split.
    • CEO, James Nantanielsz, published two articles in Pharma Trade Media.
    • Six patent proposals currently submitted covering several important discoveries regarding proenzymes and their anti-cancer effects.
    • International Research and Development Partnerships with Universities in the US, Spain, Australia, and England for joint intellectual property ownership.
    • Development of manufacturing process of drug for human use.

PPCB 2017 Q2 Milestones

  • Preparation has begun for their First-In-Man studies.
  • Filed a Patent Cooperation Treaty in April of 2017, seeking a single international patent approval for PRP that would simultaneously approve PRP in multiple countries.
  • Received a Written Opinion from an International Search Authority regarding the novelty, inventive step, and industrial applicability of PRP,  this can guide national patent offices with their patent granting decisions.
  • Propanc’s Chief Executive Officer, James Nathanielsz, was interviewed on SmallCapVoice.com.
  • Changed their ticker symbol to PPCB signifying their name change.
  • PRP entered the Investigational Medical Product Manufacture (IMP) Stage.
  • Merck Oncology’s fast track cancer treatment drug sets the stage for PRP to saturate the global cancer treatment market.
  • PRP is granted Orphan Drug Designation from the FDA

PPCB 2016 Milestones 

    • Prepared and submitted four new patents relating to the dosing, anti-cancer effects and mechanisms of the two proenzymes against various cancers in Australia and Spain.
    • Executed a manufacturing agreement with AmatsiQBiologials in Belgium beginning the process for the finished product of PRP for human use.
    • Completed 14-day, dose range toxicity study in rats determining maximum toleration for further studies.
    • Developed an enzyme linked immunosorbent assay (ELISA) method.
    • Developed and validated a new IR (infrared) dye-labelled detection method for typsinogen and chymotrypsinogen.
    • Commenced the in-life phase of a GLP-compliant, 28-day repeat dose-toxicity study for PRP in rats, which is expected to help define the safe starting dose in advanced cancer patients for the first-in-man studies.

Conclusion

PPCB‘s treatment has investors and medical professionals alike, extremely excited.  As an investment opportunity, the stock has found support since completing its reverse split, which signals a potential move to a higher exchange.  Getting involved as soon as possible could be extremely lucrative for investors as PRP heads toward its First-In-Man.

Please Sign Up To Receive Updates on PPCB

11 + 6 =

Scottrade

ChoiceTrade

TradeMonster

TradeKing

Cobra

Fidelity

USAA

etrade

CharlesSchwab

TDAmeritrade

Sharebuilder

InteractiveBrokers

IMPORTANT NOTICE AND DISCLAIMER
Wealth and Knowledge Report is owned by Upstate Web Writers Inc “UWW”. UWW  is an information and marketing firm and is not a financial analyst, investment advisor or broker/dealer. We are in the business of marketing and advertising companies to generate exposure of them by sending alerts to our subscribers for monetary compensation.
The content of this report compiled by UWW is paid advertising and does not purport to provide an analysis of the featured company’s financial position, operations or prospects. Because this advertisement has not been prepared with any one individuals financial condition or investment goals in mind it is not to be construed as a recommendation or solicitation by UWW Inc. to buy or sell any security. UWW has been compensated $5,000 by Regal Consulting for the purpose of increasing public awareness of PPCH. UWW has not investigated the background of the hiring company. Anyone viewing this newsletter should assume the hiring party or affiliates of the hiring party own shares of the company mentioned which they plan to liquidate, further understanding that the liquidation of those shares may or may not negatively impact the share price.
Viewers of this report should understand that trading activity and stock prices in many if not all cases tend to increase during the advertisement campaigns of the profiled companies and in many if not all cases tend to decrease thereafter. This tends to create above average volatility and price movements in the profiled company’s stock during the advertisement campaign that viewers should take into consideration at all times. Campaigns vary in length, and many are for short periods of time, typically less than a week.
Investing in securities is highly speculative and carries a great deal of risk, especially as to newer companies with comparatively short operating histories and limited earnings. You may lose your entire investment. If you cannot afford to lose your entire investment do NOT invest in penny stocks. UWW nor any of its officers or principals or affiliates (as defined in the Securities Act of thirty three, as amended, and Rule 501(b) promulgated there under) will ever own or beneficially own any securities of any company mentioned in this email. We are advertisers, not investors or traders. This advertisement is based entirely upon information gathered from public information and third party websites. Although the information contained in this e-mail is believed to be reliable. UWW makes no warranties as to the accuracy of the content of this e-mail, expressly disclaims and accepts no liability for how readers may choose to utilize the content of this e-mail. Readers are strongly urged to independently verify all statements made in this advertisement and to perform their own due diligence on this or any other advertised company, including but not limited to consulting with a qualified investment professional, reviewing the publicly available financial statements of, and other information about these featured companies and verifying that an investment in that company is appropriate and suitable for you. Featured companies are traded on the OTC Bulletin Board or Pink Sheets and their stock is registered under the Securities Act of thirty three, as amended, and its periodic and other reports filed under the Securities Exchange Act of thirty four, as amended, are publicly available from the Securities and Exchange Commission at its website at http://www.sec.gov, which also contains general investor information about publicly-traded companies, advice to investors and other investor resources. Other investor resources are available from the Financial Industry Regulatory Authority through its website at http://www.finra.org. Many states have established rules requiring approval by the state securities administrator to permit sales of a security to its residents. Check with the North American Securities Administrators Association through its website at http://www.nasaa.org or call your state securities administrator to determine whether a particular security may be purchased by you as a resident of your state. Many companies have filed information with state securities regulators and many companies will supply prospective investors with additional information upon request. This advertisement contains forward-looking statements about the featured company its business and prospects. Such forward-looking statements are within the meaning of Section Twenty Seven A of the Securities Act of thirty three, as amended, and Section Twenty One E of the Securities Exchange Act of thirty four, as amended, and are intended to be covered by the safe harbor provisions created by these laws. Where a featured company expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis.
UWW is required by the FTC to inform you that a relationship exists between this website and some of the products or services it reviews, recommends or promotes. It is advisable to assume that any mention of a product or service on this website is made because there exists, unless otherwise stated, a material connection between the product or service owners and this website. It should be understood that any recommendation made by the owner of this site for any product or service has been made in good faith. These recommendations reflect the fact that the owner has either tried the product or service or has extensively researched them and can give an honest opinion to the merit of the product or service. When any website makes any recommendation of a product or service it is advisable to assume the possibility of a material connection or relationship with the owners of those products or services. Due to the material connection between the owner of this website and the owners of the products or services recommended here, it must be understood that a bias for these products or services might exist. These biases, although based on facts, could have developed because of compensation for such recommendations from the product or service owners although every effort has been made to provide accurate and true reviews of each product or service. Regardless of whether the owner of this website has, or will receive compensation from product or service owners, it should be understood that a relationship exist between the two so there does exist, established or not, the potential for a material connection between product and service owner and the owner of this website. Before entering into any agreement or purchasing any product from this website, it is advisable to understand the potential partiality of the website owner due to possible compensation from the owner’s of products or services recommended on this website. You should perform your own research and exercise due diligence prior to purchasing products or services from any website. The owner of this website may receive compensation for recommendations made in reference to the products or services on this website or page. This compensation may be in the form of money, services or complimentary products and could exist without any action from a website visitor. Should you purchase a product or service that was recommended by this website, it is understood that some form of compensation might be made to the website owner. For example, if you click on an affiliate link at this website and then make a purchase of the recommended product or service, the website owner may receive compensation. This Compensation disclosure statement has been made to inform you of the possibility that a material connection between a product or service mentioned, reviewed or recommended by this website and the product or service owner exist and that compensation to the website owner may be made should you purchase such product or service. Every effort has been made to provide true and accurate statements in regards to any and all products or services mentioned, reviewed or recommended by this website.